Regional, provider, and economic factors associated with the choice of active surveillance in the treatment of men with localized prostate cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 213-220

  Hamilton, Ann S ^a   Wu, Xiao Cheng ^b   Lipscomb, Joseph ^c   Fleming, Steven T ^d   Lo, Mary ^a   Wang, Dian ^e   Goodman, Michael ^c   Ho, Alex ^f   Owen, Jean B ^f   Rao, Chandrika ^g   German, Robert R ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f AMERICAN COLLEGE OF RADIOLOGY   (United States)

^g State Center for Health Statistics   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SOCIOECONOMICS; UNITED STATES; UROLOGIST; BLOOD; DECISION MAKING; DECISION SUPPORT SYSTEM; DOCTOR PATIENT RELATION; EARLY DIAGNOSIS; MIDDLE AGED; PATIENT PARTICIPATION; PROSTATE TUMOR; PROSTATECTOMY; SOCIAL SUPPORT; WATCHFUL WAITING;

PROSTATE SPECIFIC ANTIGEN;

AGED; CHOICE BEHAVIOR; DECISION MAKING; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIAL SUPPORT; WATCHFUL WAITING;

EID: 84871781577     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs033     Document Type: Article

References (24)

1. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771.
2. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-374.
3. Brawley OW. The prostate cancer quandary. American Cancer Society Web site. http://www.cancer.org/Cancer/News/ExpertVoices/post/2011/10/05/The-Prostate-Cancer-Quandary.aspx. Published June 29, 2011. Updated October 5, 2011. Accessed July 10, 2012.
4. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep. 2010;11(3):165-171.
5. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol. 2010;7(7):394-400.
6. Suardi N, Capitanio U, Chun FK, et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer. 2008;113(8):2068-2072.
7. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373-2380.
8. Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology. 2011;77(3):588-591.
9. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE Database. J Urol. 2008;180(4):1330-1335.
10. Jang TL, Bekelman JE, Liu Y, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010;170(5):440-450.
11. Brewster SF. Low-risk localized prostate cancer: are we ready to tell patients that active surveillance is the preferred option? BJU Int. 2008;102(8):923-926.
12. German RR, Wike JM, Bauer KR, et al. Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study. J Registry Manag. 2011;38(2):75-86.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer 2002. http://www.nccn.org/clinical.asp. Accessed August 1, 2012.
14. Piccirillo JF, Creech C, Zequeira R, Anderson S, Johnson AS. Inclusion of comorbidity into oncology data registries. J Registry Manag. 1999;26(2):66-70.
15. Johnson AS, Piccirillo JF, Creech C, et al. Validation of a comorbidity education program. J Registry Manag. 2001;28(3):125-131.
16. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D. The measurement of comorbidity by cancer registries. J Registry Manag. 2003;30(1):8-14.
17. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL, Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2006;291(20):2441-2447.
18. Byers TE, Wolf HJ, Bauer KR, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patters of Care Study. Cancer. 2008;113(3):585-591.
19. Area Resource File (ARF). National County-level Health Resource Information Database. Rockville, MD: Health Resources and Services Administration; 2009. http://arf.hrsa.gov. Accessed July 10, 2012.
20. US Population Data - 1969-2009. SEER: Surveillance Epidemiology, and End Results Web site. http://seer.cancer.gov/popdata/index.html. Published January 21, 2011. Accessed July 10, 2012.
21. Caldwell D. Medicare physician identifiers UPINs, PINs and NPI numbers. http://www.resdac.org/tools/TBs/TB-002_MedicarePhysicianIdentifiers_ 508.pdf. Research Data Assistance Center Publication Number TB-002. Published January 2003. Accessed July 10, 2012.
22. Ramsey SD, Zeliadt SB, Fedorenko CR, et al. Patient preferences and urologists recommendations among local stage prostate patients who present for initial consultations and second opinions. World J Urol. 2011;29(1):3-9.
23. Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in treatment of localized prostate cancer using supplemented cancer registry data. BJU Int. 2011;107(4):576-584.
24. Dall'Era MA, Konety BR. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nat Rev Clin Oncol. 2008;5(5):277-283.